Larson Financial Group’s Inspire Medical Systems INSP Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$15.5K Buy
348
+210
+152% +$9.96K ﹤0.01% 2157
2026
Q1
$7.12K Buy
138
+94
+214% +$6.58K ﹤0.01% 2426
2025
Q4
$4.06K Sell
44
-597
-93% -$57.1K ﹤0.01% 2535
2025
Q3
$47.6K Buy
641
+638
+21,267% +$64.6K ﹤0.01% 1186
2025
Q2
$389 Sell
3
-6
-67% -$870 ﹤0.01% 2921
2025
Q1
$1.43K Buy
9
+4
+80% +$724 ﹤0.01% 2276
2024
Q4
$927 Buy
+5
New +$971 ﹤0.01% 2058
2024
Q1
Sell
-1
Closed -$203 1851
2023
Q4
$203 Hold
1
﹤0.01% 1653
2023
Q3
$198 Hold
1
﹤0.01% 1637
2023
Q2
$325 Hold
1
﹤0.01% 1476
2023
Q1
$234 Hold
1
﹤0.01% 1460
2022
Q4
$252 Hold
1
﹤0.01% 1414
2022
Q3
$0 Buy
+1
New +$201 ﹤0.01% 1343
2022
Q2
Sell
-50
Closed -$13K 1240
2022
Q1
$13K Buy
+50
New +$11.4K ﹤0.01% 595

Other funds holding INSP

Larson Financial Group's INSP Position: Q2 2026 in Review

Larson Financial Group increased its Inspire Medical Systems (INSP) stake by 152% in Q2 2026, buying an estimated $9.96K and bringing the position to 348 shares worth $15.5K. The position accounts for ﹤0.01% of the portfolio, ranked #2157.

Larson Financial Group first reported a position in INSP in Q1 2022 and has held it in 14 quarters since. The position peaked at $47.6K in Q3 2025. 275 funds tracked by Wall St. Rank hold INSP as of Q2 2026.

  • Larson Financial Group held 348 shares of Inspire Medical Systems worth $15.5K as of Q2 2026.
  • Larson Financial Group bought 210 Inspire Medical Systems shares in Q2 2026, an estimated $9.96K.
  • Inspire Medical Systems made up ﹤0.01% of Larson Financial Group's portfolio in Q2 2026, its #2157 holding.
  • Larson Financial Group first reported a position in Inspire Medical Systems in Q1 2022 and has held it in 14 quarters since.
  • Larson Financial Group's Inspire Medical Systems position peaked at $47.6K in Q3 2025.
  • 275 funds tracked by Wall St. Rank held Inspire Medical Systems as of Q2 2026.

Based on Larson Financial Group's 13F filing for Q2 2026, filed 14 Aug 2026.